Boston Scientific Corporation

(New York Stock Exchange)
Back to all articles
Bearish -60

Boston Scientific stock faces negative outlook as growth slows

Acquisition Financial outlook AI-generated analysis

πŸ“‰ S&P Global Ratings revised Boston Scientific's credit outlook to negative from stable due to pressure on WATCHMAN and electrophysiology franchises.

πŸ’° The planned 14.5 billion US dollar acquisition of Penumbra is expected to close in early 2027, adding significant leverage risk.

πŸ“Š Revenue growth forecasts were lowered to 4.4 percent for 2026 and 9 percent for 2027, below the mid- to high-teens rates seen previously.

βš–οΈ Adjusted leverage is projected to rise above 3.6 times after the Penumbra deal closes, well above the 2.5-times downside trigger.

πŸ’Έ The company plans to pursue 500 million US dollars in restructuring savings through 2029 to manage financial policy and integration costs.

🎯 Management aims to work back toward a leverage ratio of 2.5 times by the end of 2028, contingent on successful execution.

πŸ₯ Investors are focused on whether the broader portfolio can offset weakness in two important growth franchises while integrating Penumbra.

Risk Factors
  • S&P Global Ratings revised Boston Scientific's credit outlook to negative from stable, citing pressure on WATCHMAN and electrophysiology franchises.
  • The planned 14.5 billion US dollar acquisition of Penumbra is expected to push adjusted leverage above 3.6 times after closing, exceeding the 2.5-times downside trigger.
  • Revenue growth forecasts were lowered to 4.4 percent for 2026 and 9 percent for 2027, representing a significant deceleration from mid- to high-teens growth rates achieved in 2024 and 2025.
  • The negative outlook depends on the company's ability to stabilize WATCHMAN, restore electrophysiology growth, and successfully integrate Penumbra while maintaining conservative financial policy.
Full Analysis
S&P Global Ratings has revised Boston Scientific's credit outlook to negative from stable, citing weakening growth in its WATCHMAN and electrophysiology franchises. The agency affirmed the company's A- issuer rating but highlighted concerns over pressure on these two key business segments which have historically driven significant expansion. The medical device maker faces a planned acquisition of Penumbra for 14.5 billion US dollars, expected to close in early 2027. S&P projects that this deal will push the company's adjusted leverage above 3.6 times after closing, significantly exceeding its 2.5-times downside trigger and keeping debt levels elevated for an extended period. Revenue growth forecasts have been lowered to 4.4 percent for 2026 and 9 percent in 2027, marking a decline from the mid- to high-teens growth rates achieved in 2024 and 2025. Management plans to pursue approximately 500 million US dollars in restructuring savings through 2029 to manage costs while integrating Penumbra and stabilizing core franchises. The central challenge for investors is whether Boston Scientific's broader portfolio can offset the specific pressures in its WATCHMAN and electrophysiology units. The negative outlook depends on successful integration of Penumbra, restoration of growth in key areas, and a return to leverage targets by the end of 2028.